Move brings together AstraZeneca and Alexion colleagues in a purpose-built facility in Kendall Square, Cambridge, MA, a world-leading life sciences hub
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations.
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
New inhalers would have near-zero Global Warming Potential propellant
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)